CureVac AG : Curevac is a private German mRNA company with a diversified pipeline, and three lead programs in ph1: CV8102 (various cancer indications), CV9202 (NSCLC) and CV7202 (Rabies). mRNA-based antibody delivery deal with Genmab (Dec'19) provides further technology validation. Other companies in the space: MRNA, TBIO, BNTX.
• Lead Programs:
o CV8102 (melanoma, adenoidcystic carcinoma, sq cell cancer of skin and H&N) in Ph 1
 Ph1 readout mid-2021
 Ph2 initiation 2H 2021
o CV9202 (NSCLC) in Ph 1
o CV7202 (Rabies) in Ph 1
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Europe
Clinical Stage
Phase l or ll
Disease Space
Anti-infectives, Antivirals, Autoimmune, Oncology
Finance
Pre-Revenues
Industry
Biotechnology
Listing
Public, USA
Market Cap
1B +
Therapeutic Modalities
Platform Technology, Vaccine
Website:
Profiles:
Address:
Paul-Ehrlich-Straße 15
Tübingen, Baden-Wurttemberg 72076
Germany

Upcoming Company Event Participation

2020 Wall Street "On Tap"

Virtual, October 1, 2020

Top 10 Holders of CureVac N.V.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Apo Asset Management GmbH 0.01 15,300 0.80 Funds 8/31/20
Bellevue Asset Management AG 0.01 14,000 0.73 Funds 8/31/20
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.